Aldeyra Therapeutics announced advancement of new RASP modulators and recent preclinical data in obesity in conjunction with an Investor Roundtable scheduled. Pipeline Updates: Following positive biomarker results in adults, including near-normalization of lipid profiles, ADX-629, a first-in-class orally administered investigational RASP modulator, advanced to the pediatric cohort of the Phase 2 clinical trial in Sjogren-Larsson Syndrome. Top-line results from approximately five pediatric patients are expected in 2025. Based on new results in a preclinical model of obesity, novel RASP modulator ADX-743 was advanced to Investigational New Drug-enabling studies. Pending additional results, Aldeyra expects to submit an IND application for ADX-743 or an alternative RASP modulator for obesity or hypertriglyceridemia in 2025. ADX-248 will be advanced in lieu of ADX-246 to Phase 1/2 clinical testing in atopic dermatitis. Phase 1 clinical testing of ADX-248 is expected to begin in the second half of 2024. Novel RASP modulator ADX-631 has initiated preclinical testing in models of retinal disease. Aldeyra expects to submit an IND application for ADX-631 or an alternative RASP modulator for the treatment of dry AMD or geographic atrophy in the first half of 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALDX:
Questions or Comments about the article? Write to editor@tipranks.com